Fosun Pharmaceutical Gets US FDA Orphan Drug Designation for Anti-Tumor Drug
MT Newswires Live
Oct 20
The US Food and Drug Administration granted Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) orphan drug designation for its HLX43 drug for advanced or metastatic solid tumors, according to a Saturday filing with the Shanghai bourse.
Shares rose 2% in Hong Kong during afternoon trading on Monday.
The FDA designation will support research and development, registration, and commercialization support for the drug's indication for thymic epithelial tumors in the U.S., the filing said.
Fosun will also be exempted from new drug application fees and will obtain seven-year drug exclusivity, its said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.